To this end, we generated PDXs from seven independent ER/Her2-positive breast cancer patients in female athymic NMRI nu/nu mice, and treated these with either the PI3Kα specific inhibitor BYL719 (35 mg/k 6IW) or with vehicle during a total of 12 days. Here, ERBB2 is linked to breast cancer.